Evidence map›Paper›PMID 40708720›Full record

ReviewFrontiers in endocrinology2025

Homocysteine and thyroid diseases.

Lili Cui, Fei Wang, Chunyu Li, Fan Liu, Haipeng Wang, Junyu Zhao

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lili Cui *Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Shandong Key Laboratory of Rheumatic Diseaseand Translational Medicine, Shandong Institute of Nephrology, Jinan, China.
Fei Wang *Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Shandong Key Laboratory of Rheumatic Diseaseand Translational Medicine, Shandong Institute of Nephrology, Jinan, China.
Chunyu LiDepartment of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Shandong Key Laboratory of Rheumatic Diseaseand Translational Medicine, Shandong Institute of Nephrology, Jinan, China.
Fan LiuDepartment of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Shandong Key Laboratory of Rheumatic Diseaseand Translational Medicine, Shandong Institute of Nephrology, Jinan, China.
Haipeng WangCollege of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Junyu ZhaoDepartment of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Shandong Key Laboratory of Rheumatic Diseaseand Translational Medicine, Shandong Institute of Nephrology, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Homocysteine (Hcy) is an important intermediate product in methionine metabolism which plays a key role in the methylation of DNA, RNA and proteins. High level of Hcy can induce endothelial cell damage, promote the release of inflammatory factors, stimulate oxidative stress and inhibit the fibrinolytic system. Numerous studies have confirmed the close relationship between hyperhomocysteinemia (HHcy) and the occurrence/development of various diseases such as cardiovascular diseases, neurological disorders, thrombotic diseases, and tumors. With the rising incidence of thyroid diseases, the relationship between Hcy and thyroid diseases has attracted widespread attention. It has been found that HHcy may be directly or indirectly associated with the development of hypothyroidism, but the findings with hyperthyroidism, chronic lymphocytic thyroiditis and reduced thyroid hormone sensitivity are controversial. This article reviews the research progress of Hcy and thyroid diseases, with a view to providing new ideas for the prevention and clinical treatment of diseases.

Indexed as

HomocysteineHyperhomocysteinemiaThyroid DiseasesAnimalsHumansHomocysteinehomocysteinehyperhomocysteinemiahyperthyroidismhypothyroidismMTHFR

Identifiers

PMID40708720
PMCPMC12286808

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.